Revolution Medicines, Inc. (RVMD) shares rose 2.1% to $209.87 as of September 2, 2026, a modest gain from the prior close of $205.57. BestStocks flagged the session as a major change for RVMD. Below, we break down what changed for RVMD, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
RVMD climbed 2.1% to $209.87
RVMD rose 2.1% in its latest session, moving from $205.57 to $209.87.
ValuationLow confidence
Rel. volume
0.7×
Below Avg
Vs peers
—
No comparable peers
Market cap
$44.6B
NASDAQ Global Select
Analyst target
$248
+18.0% vs price
Price chart
Aug 3 – Sep 1
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Revolution Medicines, Inc. investors
For Revolution Medicines, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 2.1% session move. Weighing against that: Revolution Medicines, Inc. (RVMD) moved -3.10% from $186.16 to $180.39 on 2026-07-20; Revolution Medicines, Inc. (RVMD) moved -2.85% from $184.44 to $179.18 on 2026-07-16. Wall Street's consensus price target sits at $247.69, implying +18.0% upside from $209.87. BestStocks rates the overall signal quality low (41/100). With earnings roughly 63 days out, the next report is the most likely near-term test of the move.
RVMD price reaction
RVMD last traded at $209.87, up $4.30 (+2.09%) from the previous close of $205.57. The session traded on 0.7× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $182.45 and $221.15, and it currently sits about 71% of the way up that band.
Bullish and bearish analyst opinions on Revolution Medicines, Inc. (RVMD)
The consensus analyst price target on Revolution Medicines, Inc. (RVMD) is $247.69, 18.0% above the recent $209.87. Over the past 90 days analysts logged 0 upgrades, 16 maintains, and 0 downgrades. Here is how the bullish and bearish cases on RVMD line up.
▲ The bullish case
+Wall Street's consensus price target of $247.69 implies +18.0% upside from $209.87.
+The Street's most bullish target is $320.00 (+52.5%).
+Material positive event.
+Positive 2.1% session move.
+Revolution Medicines, Inc. (RVMD) moved +3.90% from $179.18 to $186.16 on 2026-07-17.
▼ The bearish case
−The most bearish analyst target is $179.00 (-14.7%).
−Revolution Medicines, Inc. (RVMD) moved -3.10% from $186.16 to $180.39 on 2026-07-20.
−RVMD fell 3.04% to $186.76 on below-average volume (0.47x expected at 90 minutes into the session).
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 1, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Revolution Medicines, Inc. (RVMD) moved +2.56% from $204.64 to $209.87 on 2026-09-01. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average at 0.7x.
The U.S. FDA approved Revolution Medicines' oral cancer drug RASONQUE (daraxonrasib) for previously treated metastatic pancreatic cancer, marking the first broad RAS-targeted medicine cleared for this indication, according to Barron's. The stock rose 2.33% from $215.44 to $220.47 intraday on the regulatory milestone and investor enthusiasm for the precision oncology validation.
Revolution Medicines rose 2.99% to $217.69, extending momentum driven by strong clinical progress on daraxonrasib (RMC-6236), its lead experimental drug for metastatic pancreatic cancer. The FDA's acceptance of the drug's NDA and grant of priority/breakthrough status, combined with a recent strategic partnership with BeOne Medicines for clinical development and Asia commercialization, have fueled sustained investor enthusiasm. Volume of 1.91M shares ran 1.73x above historical average, indicating above-typical engagement.
Material / Earnings2026-08-18+1.9%
Revolution Medicines, Inc. (RVMD) moved +3.28% from $209.15 to $216.00 on 2026-08-18, reaching a new 30-day high. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Revolution Medicines (RVMD) rallied 4.02% to an all-time high of $211.89, driven by momentum around its late-stage RAS(ON) inhibitor pipeline, a raised Guggenheim price target to $240, recent institutional investments, and a regional partnership with BeOne Medicines (per web synthesis and investing.com/Yahoo Finance). Volume of 537,807 shares sits below average for this time of session.
Revolution Medicines rose 2.17% to $202.11, driven by strong investor sentiment around daraxonrasib momentum and recent analyst price target increases. RBC Capital raised its price target to $203 citing strong daraxonrasib uptake and best-in-class KRAS pipeline prospects (MarketWatch). The stock is trading near 52-week highs, supported by EMA phased review initiation for daraxonrasib in metastatic pancreatic cancer and an nearing-completion rolling FDA NDA submission. Volume of 858,901 shares remained below average at 0.60x expected.
Material / Earnings2026-08-05+2.0%
Revolution Medicines, Inc. (RVMD) reported EPS of −$3.06 vs. −$2.04 consensus estimate for Q2 FY2026 on August 5, 2026, missing by 50%.
Filings2026-08-05+2.0%
Revolution Medicines, Inc. (RVMD) filed a new 8-K on 2026-08-05. The filing content was not detailed in available sources.
Upcoming catalysts & outlook
Next earnings
2026-11-04 (est.)
in 63 days
Thesis shift
Neutral / Mixed
bullish signal
Risk level
High
from change events
Frequently asked questions about RVMD
Why did Revolution Medicines, Inc. (RVMD) stock move?
RVMD rose 2.1% to $209.87. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did RVMD stock rise?
RVMD gained 2.09% ($4.30) versus the prior close of $205.57, last trading at $209.87 on 0.7× average volume.
When is Revolution Medicines, Inc.'s next earnings date?
RVMD's next earnings report is estimated for 2026-11-04 — about 63 days away.
What is the analyst price target for RVMD?
The consensus analyst price target for RVMD is $247.69, about 18.0% above the current $209.87. Over the past 90 days, analysts recorded 0 upgrades, 16 maintains, and 0 downgrades.
How BestStocks tracks RVMD
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared RVMD-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for RVMD, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 2, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
